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Weighing for results: assessing the effect of IPTp
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Although earlier studies showed that intermittent preventive therapy in pregnancy (IPTp) 
with sulfadoxine–pyrimethamine provides substantial benefit to pregnant women and their 
infants, the spread of resistance raises questions about how long the therapy is efficient for.1 
In their meta-analysis, Thomas Eisele and colleagues2 show that IPTp with sulfadoxine–
pyrimethamine continues to provide substantial benefits, resulting in a 26% reduction in low 
birthweight and a 16% reduction in neonatal mortality under programme conditions. How 
ever, the absence of exact birthweight data in many of the surveys is an important limitation. 
Mothers tend to overestimate weight; therefore, the prevalence of low birthweight is 
underestimated.3 The effect of IPTp with sulfadoxine–pyrimethamine and insecticide-treated 
nets (ITNs) on low birthweight can be underestimated when mothers’ perception of weight 
is used as a proxy for measured birthweight. Despite this limitation, the study shows how 
useful birthweight data from cross-sectional surveys are to monitor effectiveness of 
interventions nationally, and emphasises the importance of obtaining accurate birthweight 
information on all infants.
The authors suggest that the effect of IPTp on neonatal mortality could be explained by 
increased birthweight. However, a clinical trial of IPTp with sulfadoxine–pyrimethamine 
found a marked reduction (61·3%) in neonatal mortality without an effect on birthweight, 
suggesting that the treatment affects neonatal survival through mechanisms independent of 
increased birthweight.4 In the study by Eisele and colleagues, the effect of ITN use during 
pregnancy was probably underestimated because household ownership was used as a proxy 
for use and because of the overlapping definitions of full and partial coverage. Other studies 
have provided indisputable evidence that ITNs protect against the adverse effects of malaria 
in pregnancy; therefore, this intervention should not be discounted on the basis of the results 
of this study.5 The uptake of IPTp with sulfadoxine–pyrimethamine has been slow in many 
countries and substantial improvement in IPTp coverage is needed. Collaboration between 
national malaria control and reproductive health programmes is needed to improve the 
delivery of IPTp. The recent WHO guidelines calling for administration of IPTp with 
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sulfadoxine–pyrimethamine at each scheduled antenatal care visit starting in second 
trimester will hopefully improve coverage.6
The report by Eisele and colleagues emphasises the importance of IPTp with sulfadoxine–
pyrimethamine and ITN use in pregnancy. The findings are similar to nationally 
representative population-based data across many settings, which represent the real world of 
malaria programming. These findings support the idea that prevention of malaria in 
pregnancy is a crucial part of both malaria and reproductive health programmes, and merit 
increased scale-up.
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